Search the Newsreel

Why CareDx (CDNA) Is Up 33.8% After Strong Q2 Profit, Higher 2026 Outlook And ESOP Shelf

CareDx reported strong Q2 2026 results with significant revenue and net income increases, leading to a 33.8% stock surge. The company raised its full-year 2026 revenue outlook to US$490 million–US$500 million and filed an US$80.30 million shelf registration for an employee stock ownership plan. …

GeneDx (NASDAQ:WGS) Shares Gap Up on Better-Than-Expected Earnings

GeneDx Holdings Corp (WGS) (Q2 2026) Earnings Call Highlights: Record Volume and Early ...

This article first appeared on GuruFocus. Total Revenue: $114.4 million, up 11% year-over-year. Exome and Genome Revenue: $100.3 million, up 17% year-over-year. Exome and Genome Test Volume: 30,785 tests, up 32% year-over-year. Gross Margin: 70%, up sequentially from 69% in the first quarter. Adjusted …

GeneDx Holdings (WGS) Is Up 9.7% After Beating Q2 Estimates And Reaffirming 2026 Outlook - Has The Bull Case Changed?

Genedx reaffirms 2026 revenue guidance of $475M-$490M while expecting meaningful collection-rate uplift starting in Q4

Earnings Call Insights: GeneDx Holdings Corp. (WGS) Q2 2026 MANAGEMENT VIEW * “We hit a new record, resulting more than 30,000 exome and genome tests in the quarter, which represents 32% year-over-year growth. We reported $114.4 million of total revenue, exceeding our guide, and …

[10-Q] GeneDx Holdings Corp. Quarterly Earnings Report

GeneDx Holdings Corp. (WGS) filed its quarterly earnings report (Form 10-Q) for the period ended June 30, 2026. The report details a new financing structure involving an amended loan agreement for an additional $50 million, increasing debt capacity to $150 million, and a conditional …

GeneDx Reports Second Quarter 2026 Financial Results

Reported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue Reported exome and genome volume growth of 32% year-over-year Reported adjusted gross margin(1) of 70% and adjusted net income(1) of $0.4 million Reiterating full year 2026 revenue guidance …

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

Faruqi & Faruqi, LLP reminds investors of the August 3, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS). The lawsuit alleges that GeneDx and its executives made false and misleading statements regarding …

CareDx climbs another 9% after guidance raise, sets new 52-week high (CDNA:NASDAQ)

CareDx (CDNA) shares rallied over 9%, extending a previous 15% surge, after the company raised its full-year revenue guidance and reported strong second-quarter results. The precision medicine diagnostics company, focused on transplant patients, reached a new 52-week high. Key drivers include testing services segment …

CareDx Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against CareDx Inc. (NASDAQ: CDNA) and reminds investors of the July 22, 2022 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that CareDx engaged in improper schemes …

GeneDx Holdings (Nasdaq: WGS) grows Q2 2026 revenue to $114.4M amid GAAP loss

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased securities between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made materially false and misleading statements regarding …

CareDx (CDNA) Following Raised Guidance And Profit Swing, Does The Stock Look Fully Valued

MiMedx Group Number of Employees 2026 | Employee Count & Headcount Data

MiMedx Group (NASDAQ: MDXG) had 799 employees globally as of March 2026, representing a 1.0% decline since 2023. The company is actively hiring, with 40 active job postings in 2026, though new postings are slowing. The workforce is primarily concentrated in the United States, …

WGS Deadline: WGS Investors with Losses in Excess of $100K Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit

The Rosen Law Firm is reminding investors who purchased common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025, and May 4, 2026, of the August 3, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that GeneDx made …

WGS DEADLINE MONDAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 3 Deadline in Securities Class Action - WGS

NEW YORK, Aug. 01, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”), of the important …

GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Kahn Swick & Foti, LLC (KSF) has reminded investors of GeneDx Holdings Corp. (NASDAQ: WGS) with substantial losses that they have until August 3, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that GeneDx and its executives …

Key facts: CareDx (CDNA) raises 2026 revenue guide; grants 15,822 RSUs

GeneDx Holdings Corp. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against GeneDx Holdings Corp. - WGS

Kahn Swick & Foti, LLC (KSF) is reminding investors in GeneDx Holdings Corp. (NasdaqGS: WGS) that they have until August 3, 2026, to apply for lead plaintiff in a securities class action lawsuit. The lawsuit alleges that GeneDx and its executives made false and …

CareDx (CDNA) Stock Jumps As Profitability Recasts The Growth Story

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx, Inc. (Nasdaq: CDNA) has announced inducement grants of 15,822 restricted stock units (RSUs) to James McNally, their newly appointed Executive Advisor. These RSUs were granted under the Company's 2025 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are …

Renaissance Technologies LLC Has $11.93 Million Stake in MiMedx Group, Inc $MDXG

Renaissance Technologies LLC increased its stake in MiMedx Group, Inc (MDXG) by 22.4% in the first quarter, now holding 3.02 million shares valued at $11.93 million, representing 2.03% of the company. Despite some recent analyst price target reductions and downgrades, the stock maintains a …

GENEDX HOLDINGS DEADLINE MONDAY AUGUST 3rd: Bragar Eagel & Squire, P.C. Urges GeneDx Holdings Corp. Investors to Contact the Firm Regarding Lead Plaintiff Deadline

Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GeneDx Holdings Corp. (NASDAQ:WGS) for alleged federal securities law violations. The lawsuit claims GeneDx made false and misleading statements about its business, leading to a significant drop in stock price after the …

CareDx: Q2 Earnings Snapshot

This article provides a Q2 earnings snapshot for CareDx. Unfortunately, the content of the article itself is missing, preventing a detailed summary of the financial performance or key highlights.

CareDx (NASDAQ:CDNA) Announces Earnings Results, Beats Estimates By $0.15 EPS

CareDx (NASDAQ:CDNA) Sets New 1-Year High After Strong Earnings

CareDx Announces Second Quarter 2026 Financial Results

CareDx, Inc. reported strong second-quarter 2026 financial results, with a 52% year-over-year revenue increase to $132 million and GAAP net income of $111 million. The company raised its full-year 2026 revenue guidance to $490 million to $500 million and adjusted EBITDA guidance to $66 …

Sanara MedTech (SMTI) plans business combination with MiMedx Group to build regenerative leader

Sanara MedTech (SMTI) has announced a proposed business combination with MiMedx Group, Inc., aiming to establish a leading regenerative medicine company focused on surgical and wound care applications. The transaction is expected to close by year-end, pending regulatory and shareholder approvals. Until then, both …

CDNA Looks 77.9% Overvalued on GF Value™ Amid Revenue Upgrade

Earnings Flash (CDNA) CareDx, Inc. Reports Q2 Revenue $131.9M, vs. FactSet Est of $113.8M

CareDx, Inc. (CDNA) reported Q2 revenue of $131.9 million, surpassing the FactSet estimate of $113.8 million. The company also announced adjusted EPS of $0.37 per share, significantly higher than the FactSet estimate of $0.23 per share. These financial results indicate a strong performance for …

CareDx, Inc. (CDNA) Q2 2026 Earnings

CareDx, Inc. (CDNA) reported impressive Q2 2026 earnings, significantly beating EPS and revenue expectations. The company saw a 59.5% beat on EPS with $0.37 against an estimated $0.23, and revenue reached $132 million, surpassing the $114 million estimate by 15.7%. This strong performance was …

MiMedx Group Q2 Earnings Call Highlights

MiMedx Group announced its Q2 results and the acquisition of Sanara MedTech for $35 per share, expecting the deal to close by the end of 2026. This acquisition will significantly shift MiMedx's revenue mix towards surgical products, expanding its market opportunity by an estimated …

CareDx, Inc. 2Q 2026: Revenue $131.95M, EPS $2.07— 10-Q Summary

CareDx, Inc. (CDNA) reported strong second-quarter 2026 results with revenue of $131.95 million and diluted EPS of $2.07. This performance was significantly boosted by higher testing services volume, prior-period collections, and a one-time gain of approximately $113 million from the sale of its lab …

ETFs Investing in MiMedx Group, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold shares of MiMedx Group, Inc. (MDXG). It provides a detailed table with each ETF's market value of MDXG holdings, weight in the ETF, issuer, management style, focus, expense ratio, assets under management (AUM), price, …

MiMedx Group (SMTI) details Sanara MedTech buyout and 2027 profit goals

MiMedx Group announced its plan to acquire Sanara MedTech for $35 per share, aiming to combine Sanara's surgical revenue with MiMedx's soft-tissue surgical franchise and achieve at least $20 million in annual cost synergies. Despite a 35% year-over-year net sales drop in Q2 2026 …

MONDAY DEADLINE: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - WGS

Robbins Geller Rudman & Dowd LLP announces a lead plaintiff deadline of Monday, August 3, 2026, for investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made false or misleading …